Evidence map›Paper›PMID 38534433›Full record

ArticleBiology2024

The Cardiometabolic Impact of Rebaudioside A Exposure during the Reproductive Stage.

Isabella Bracchi, Juliana Morais, João Almeida Coelho, Ana Filipa Ferreira, Inês Alves, Cláudia Mendes, Beatriz Correia, Alexandre Gonçalves, João Tiago Guimarães, Inês Falcão-Pires and 2 more

Open access · goldAbstract read
In one paragraph

Article in Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Isabella BracchiUnit of Biochemistry, Department Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.ORCID 0000-0003-1923-3579
Juliana MoraisCINTESIS, Center for Health Technology and Services Research, 4200-319 Porto, Portugal.ORCID 0000-0003-3783-6074
João Almeida CoelhoDepartment of Surgery and Physiology, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.ORCID 0000-0002-3769-8962
Ana Filipa FerreiraDepartment of Surgery and Physiology, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.ORCID 0000-0003-2080-309X
Inês AlvesDepartment of Surgery and Physiology, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.ORCID 0000-0001-8329-3758
Cláudia MendesDepartment of Surgery and Physiology, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.ORCID 0000-0002-4452-6149
Beatriz CorreiaDepartment of Surgery and Physiology, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.
Alexandre GonçalvesDepartment of Surgery and Physiology, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.ORCID 0000-0002-5386-8378
João Tiago GuimarãesUnit of Biochemistry, Department Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.ORCID 0000-0003-4836-6311
Inês Falcão-PiresDepartment of Surgery and Physiology, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.ORCID 0000-0003-1937-3782
Elisa KeatingUnit of Biochemistry, Department Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.ORCID 0000-0002-3904-9907
Rita NegrãoUnit of Biochemistry, Department Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.ORCID 0000-0002-0733-4412
Universidade do Porto · PT

Funding

Cardiovascular R&D Center UIDB/00051/2020 and UIDP/00051/2020European Regional Development Fund (ERDF) through the Northern Regional Operational Program, under the HEALTH-UNORTE project. NORTE-01-0145-FEDER-000039FCT Fundação para a Ciência e a Tecnologia. I.P. CINTESIS-UIDB/4255/2020FCT Fundação para a Ciência e a Tecnologia. I.P. RISE-LA/P/0053/2020FCT/MCTES (Foundation for Science and Technology and Ministry of Science, Technology and Higher Education) 2023.03003.BDFCT/MCTES (Foundation for Science and Technology and Ministry of Science, Technology and Higher Education) UI/BD/152306/2021
6 · The paper itself

Abstract

The consumption of non-sugar sweeteners (NSS) has increased during pregnancy. The European Food Safety Agency suggested that steviol glycosides, such as Rebaudioside A (RebA), the major sweetener component of stevia, are safe for humans up to a dose of 4 mg/kg body weight/day. However, the World Health Organization recommended in 2023 the restraint of using NSS, including stevia, at any life stage, highlighting the need to study NSS safety in early periods of development. We aimed to study the mitochondrial and cardiometabolic effects of long-term RebA consumption during the reproductive stage of the life cycle. Female rats were exposed to RebA (4 mg steviol equivalents/kg body weight/day) in the drinking water from 4 weeks before mating until weaning. Morphometry, food and water consumption, glucose and lipid homeostasis, heart structure, function, and mitochondrial function were assessed. RebA showed an atrophic effect in the heart, decreasing cardiomyocyte cross-sectional area and myocardial fibrosis without repercussions on cardiac function. Mitochondrial and myofilamentary functions were not altered. Glucose tolerance and insulin sensitivity were not affected, but fasting glycemia and total plasma cholesterol decreased. This work suggests that this RebA dose is safe for female consumption during the reproductive stage, from a cardiometabolic perspective. However, studies on the effects of RebA exposure on the offspring are mandatory.

Indexed as

cardiometabolismlactationpregnancyrebaudioside A

Identifiers

PMID38534433
PMCPMC10967885
OpenAlexW4392374853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.